Ani Pharmaceuticals Stock Performance
| ANIP Stock | USD 58.92 0.27 0.46% |
ANI Pharmaceuticals has a performance score of 5 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.63, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, ANI Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding ANI Pharmaceuticals is expected to be smaller as well. ANI Pharmaceuticals now shows a risk of 1.69%. Please confirm ANI Pharmaceuticals maximum drawdown, as well as the relationship between the accumulation distribution and market facilitation index , to decide if ANI Pharmaceuticals will be following its price patterns.
Risk-Adjusted Performance
Modest
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in ANI Pharmaceuticals are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. Even with relatively weak forward indicators, ANI Pharmaceuticals may actually be approaching a critical reversion point that can send shares even higher in March 2025. ...more
Actual Historical Performance (%)
One Day Return (0.46) | Five Day Return (2.26) | Year To Date Return 6.28 | Ten Year Return (6.54) | All Time Return (72.44) |
Last Split Factor 1:6 | Last Split Date 2013-07-18 |
1 | ANI Upgraded to Buy What Does It Mean for the Stock | 11/20/2024 |
2 | Disposition of 5834 shares by Shanmugam Muthusamy of ANI Pharmaceuticals at 66.2 subject to Rule 16b-3 | 11/27/2024 |
3 | Disposition of 7500 shares by Stephen Carey of ANI Pharmaceuticals at 55.79 subject to Rule 16b-3 | 12/17/2024 |
4 | ANI Pharmaceuticals launches Prucalopride Tablets after FDA approval ANIP | 01/02/2025 |
5 | ANI Pharmaceuticals Provides Preliminary Fourth Quarter and 2024 Financial Results and Preliminary 2025 Outlook | 01/13/2025 |
6 | Insider Selling ANI Pharmaceuticals, Inc. VP Sells 21,568.00 in Stock | 01/16/2025 |
7 | ANI Pharmaceuticals, Inc. Receives Average Rating of Buy from Analysts | 01/28/2025 |
8 | Is ANI Pharmaceuticals Stock Undervalued Right Now | 01/31/2025 |
9 | ANI Pharmaceuticals Upgraded to Hold at StockNews.com | 02/06/2025 |
| Begin Period Cash Flow | 53.2 M |
ANI |
ANI Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 5,525 in ANI Pharmaceuticals on November 18, 2024 and sell it today you would earn a total of 367.00 from holding ANI Pharmaceuticals or generate 6.64% return on investment over 90 days. ANI Pharmaceuticals is currently generating 0.1195% in daily expected returns and assumes 1.6896% risk (volatility on return distribution) over the 90 days horizon. In different words, 15% of stocks are less volatile than ANI, and 98% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
ANI Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for ANI Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as ANI Pharmaceuticals, and traders can use it to determine the average amount a ANI Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0708
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | ANIP | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 1.69 actual daily | 15 85% of assets are more volatile |
Expected Return
| 0.12 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.07 actual daily | 5 95% of assets perform better |
Based on monthly moving average ANI Pharmaceuticals is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of ANI Pharmaceuticals by adding it to a well-diversified portfolio.
ANI Pharmaceuticals Fundamentals Growth
ANI Stock prices reflect investors' perceptions of the future prospects and financial health of ANI Pharmaceuticals, and ANI Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ANI Stock performance.
| Return On Equity | -0.016 | ||||
| Return On Asset | 0.0125 | ||||
| Profit Margin | (0.01) % | ||||
| Operating Margin | (0.07) % | ||||
| Current Valuation | 1.74 B | ||||
| Shares Outstanding | 21.02 M | ||||
| Price To Earning | 43.35 X | ||||
| Price To Book | 3.05 X | ||||
| Price To Sales | 2.23 X | ||||
| Revenue | 486.82 M | ||||
| Gross Profit | 332.11 M | ||||
| EBITDA | 106.6 M | ||||
| Net Income | 18.78 M | ||||
| Cash And Equivalents | 63.38 M | ||||
| Cash Per Share | 3.89 X | ||||
| Total Debt | 285.67 M | ||||
| Debt To Equity | 0.85 % | ||||
| Current Ratio | 3.35 X | ||||
| Book Value Per Share | 20.74 X | ||||
| Cash Flow From Operations | 118.96 M | ||||
| Earnings Per Share | (0.47) X | ||||
| Market Capitalization | 1.24 B | ||||
| Total Asset | 904.42 M | ||||
| Retained Earnings | (80.13 M) | ||||
| Working Capital | 374.34 M | ||||
| Current Asset | 192.58 M | ||||
| Current Liabilities | 11.76 M | ||||
About ANI Pharmaceuticals Performance
Assessing ANI Pharmaceuticals' fundamental ratios provides investors with valuable insights into ANI Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the ANI Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 201.24 | 184.50 | |
| Return On Tangible Assets | 0.03 | 0.03 | |
| Return On Capital Employed | 0.06 | 0.06 | |
| Return On Assets | 0.02 | 0.02 | |
| Return On Equity | 0.04 | 0.04 |
Things to note about ANI Pharmaceuticals performance evaluation
Checking the ongoing alerts about ANI Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for ANI Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Over 89.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from thelincolnianonline.com: ANI Pharmaceuticals Upgraded to Hold at StockNews.com |
- Analyzing ANI Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether ANI Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining ANI Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating ANI Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of ANI Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of ANI Pharmaceuticals' stock. These opinions can provide insight into ANI Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for ANI Stock Analysis
When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.